New era of integrated cancer biomarker discovery using reverse-phase protein arrays

Satoshi S. Nishizuka, Gordon Mills

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

The ultimate goal of cancer biomarker discovery is to use individual patient-derived biochemical information to improve patients' outcomes. A recent increase in the spectrum of therapeutic options for cancer requires improved approaches to identify patients likely to benefit from them. The ability to elucidate biological characteristics of tumors and to understand both inter and intra tumoral heterogeneity using large-scale data sets generated from both model systems and patient samples provides a unique opportunity to identify useful cancer biomarkers. Since the reverse-phase protein array (RPPA) was introduced in the early 2000s, it has played a central role in a wide range of uses including cancer biology, biomarker discovery, and therapeutic target evaluation. The quantitative output from RPPAs is readily combined with that from other "omics" platforms using a variety of information-intensive approaches at the molecular and population levels. A vast and rapidly growing body of related proteomic is now publicly available, and leading researchers in the field organized the Global RPPA Society in 2011 to facilitate the sharing of resources and data. The RPPA community is embracing the new paradigm of data sharing, which is designed to accelerate the discovery of cancer biomarkers and implementation of them in cancer patient management.

Original languageEnglish (US)
Pages (from-to)34-45
Number of pages12
JournalDrug Metabolism and Pharmacokinetics
Volume31
Issue number1
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Protein Array Analysis
Tumor Biomarkers
Information Dissemination
Neoplasms
Proteomics
Research Personnel
Therapeutics
Population

Keywords

  • Biomarker
  • Cancer
  • Molecular target
  • Proteomics
  • Reverse-phase protein array

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

New era of integrated cancer biomarker discovery using reverse-phase protein arrays. / Nishizuka, Satoshi S.; Mills, Gordon.

In: Drug Metabolism and Pharmacokinetics, Vol. 31, No. 1, 01.02.2016, p. 34-45.

Research output: Contribution to journalReview article

@article{4dc5d1de0a1746ca927902fb48895a65,
title = "New era of integrated cancer biomarker discovery using reverse-phase protein arrays",
abstract = "The ultimate goal of cancer biomarker discovery is to use individual patient-derived biochemical information to improve patients' outcomes. A recent increase in the spectrum of therapeutic options for cancer requires improved approaches to identify patients likely to benefit from them. The ability to elucidate biological characteristics of tumors and to understand both inter and intra tumoral heterogeneity using large-scale data sets generated from both model systems and patient samples provides a unique opportunity to identify useful cancer biomarkers. Since the reverse-phase protein array (RPPA) was introduced in the early 2000s, it has played a central role in a wide range of uses including cancer biology, biomarker discovery, and therapeutic target evaluation. The quantitative output from RPPAs is readily combined with that from other {"}omics{"} platforms using a variety of information-intensive approaches at the molecular and population levels. A vast and rapidly growing body of related proteomic is now publicly available, and leading researchers in the field organized the Global RPPA Society in 2011 to facilitate the sharing of resources and data. The RPPA community is embracing the new paradigm of data sharing, which is designed to accelerate the discovery of cancer biomarkers and implementation of them in cancer patient management.",
keywords = "Biomarker, Cancer, Molecular target, Proteomics, Reverse-phase protein array",
author = "Nishizuka, {Satoshi S.} and Gordon Mills",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.dmpk.2015.11.009",
language = "English (US)",
volume = "31",
pages = "34--45",
journal = "Drug Metabolism and Pharmacokinetics",
issn = "1347-4367",
publisher = "Japanese Society for the Study of Xenobiotics",
number = "1",

}

TY - JOUR

T1 - New era of integrated cancer biomarker discovery using reverse-phase protein arrays

AU - Nishizuka, Satoshi S.

AU - Mills, Gordon

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The ultimate goal of cancer biomarker discovery is to use individual patient-derived biochemical information to improve patients' outcomes. A recent increase in the spectrum of therapeutic options for cancer requires improved approaches to identify patients likely to benefit from them. The ability to elucidate biological characteristics of tumors and to understand both inter and intra tumoral heterogeneity using large-scale data sets generated from both model systems and patient samples provides a unique opportunity to identify useful cancer biomarkers. Since the reverse-phase protein array (RPPA) was introduced in the early 2000s, it has played a central role in a wide range of uses including cancer biology, biomarker discovery, and therapeutic target evaluation. The quantitative output from RPPAs is readily combined with that from other "omics" platforms using a variety of information-intensive approaches at the molecular and population levels. A vast and rapidly growing body of related proteomic is now publicly available, and leading researchers in the field organized the Global RPPA Society in 2011 to facilitate the sharing of resources and data. The RPPA community is embracing the new paradigm of data sharing, which is designed to accelerate the discovery of cancer biomarkers and implementation of them in cancer patient management.

AB - The ultimate goal of cancer biomarker discovery is to use individual patient-derived biochemical information to improve patients' outcomes. A recent increase in the spectrum of therapeutic options for cancer requires improved approaches to identify patients likely to benefit from them. The ability to elucidate biological characteristics of tumors and to understand both inter and intra tumoral heterogeneity using large-scale data sets generated from both model systems and patient samples provides a unique opportunity to identify useful cancer biomarkers. Since the reverse-phase protein array (RPPA) was introduced in the early 2000s, it has played a central role in a wide range of uses including cancer biology, biomarker discovery, and therapeutic target evaluation. The quantitative output from RPPAs is readily combined with that from other "omics" platforms using a variety of information-intensive approaches at the molecular and population levels. A vast and rapidly growing body of related proteomic is now publicly available, and leading researchers in the field organized the Global RPPA Society in 2011 to facilitate the sharing of resources and data. The RPPA community is embracing the new paradigm of data sharing, which is designed to accelerate the discovery of cancer biomarkers and implementation of them in cancer patient management.

KW - Biomarker

KW - Cancer

KW - Molecular target

KW - Proteomics

KW - Reverse-phase protein array

UR - http://www.scopus.com/inward/record.url?scp=84957956910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957956910&partnerID=8YFLogxK

U2 - 10.1016/j.dmpk.2015.11.009

DO - 10.1016/j.dmpk.2015.11.009

M3 - Review article

VL - 31

SP - 34

EP - 45

JO - Drug Metabolism and Pharmacokinetics

JF - Drug Metabolism and Pharmacokinetics

SN - 1347-4367

IS - 1

ER -